Viloxazine – (46817-91-8)

Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) molecule used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.

Viloxazine acts as a selective norepinephrine reuptake inhibitor, with an elimination half-life of 2.5 hours for the immediate-release form and 7 hours for the extended-release form. It was first described in 1972.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Viloxazine
https://www.medchemexpress.com/viloxazine.html
https://www.medkoo.com/products/51715
https://go.drugbank.com/drugs/DB09185
https://www.ncbi.nlm.nih.gov/books/NBK576423/